

FDA Approves MEL 80 and VisuMax Lasers for Use in the U.S.

The FDA recently approved the MEL 80™ Excimer Laser System for vision correction eye surgery. Subsequently the FDA also approved the VisuMax™ Femtosecond Laser for refractive corneal surgery.

“The FDA approval of the MEL 80 for myopic correction is a major milestone achievement in our strategy to provide the most advanced refractive laser technologies worldwide,” said Ulrich Krauss, President and CEO, Carl Zeiss Meditec AG. “With more than 750 excimer systems already delivered to customers around the globe, CZM is well established in the market and the MEL 80 has proven itself as one of the leading excimer lasers.”

Results from clinical studies found that 93% of patients were corrected at three months to 20/20 or better visual acuity. 41% were corrected to 20/12.5 or better at six months (See related article on page 21).

The VisuMax laser utilizes the modern femtosecond laser procedure for making corneal incisions. In one clinical study, the VisuMax laser was combined with excimer laser treatment using the MEL 80 (See related article on page 19).

“Our overall strategic intent is to provide not only the most advanced technologies, but also to offer innovative systems that best meet the needs and expectations of our customers,” said Jim Taylor, President and CEO of Carl Zeiss Meditec, Inc.

